1. Report Overview

1.1 Next-Generation Antibody Therapies Overview

1.2 Global Next-Generation Antibody Therapies Market Segmentation

1.3 Why you Should Read this Report

1.4 How this Report Delivers

1.5 Main Questions Answered by This Analytical Study

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Reports

1.10 About Visiongain

2. Introduction to Next-Generation Antibody Therapies

2.1 Antibodies: An Overview

2.1.1 Monoclonal versus Polyclonal Antibodies

2.1.2 A Brief History of Antibody Drug Development

2.1.3 The Antibody Manufacturing Process

2.1.4 Trends in Antibody Development

2.2 Defining Next-Generation Antibodies

2.3 Classification of Next-Generation Antibody Therapies

2.4 The Need for Next-Generation Technologies

2.5 Development Trends for Next-Generation Antibodies

2.6 Scope of this Report

2.7 Phases of Clinical Trials

3. Next-Generation Antibody Therapies: World Market 2016-2027

3.1 The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2016

3.2 Leading Next-Generation Antibody Therapies

3.3 World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2027

3.4 How Will Segmental Market Shares Change to 2027?

3.5 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2027

4. Leading Regional Markets 2016-2027

4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2016

4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2027

4.3 How Will Regional Market Shares Change to 2027?

4.4 US Next-Generation Antibody Therapies Market 2016-2027

4.5 EU5 Next-Generation Antibody Therapies Market 2016-2027

4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2016-2027

4.7 Latin American Next-Generation Antibody Therapies Market 2016-2027

4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2016-2027

5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2016-2027

5.1 Market Overview, 2017

5.2 Leading ADCs in 2017

5.3 Antibody-Drug Conjugates: Market Forecast 2016-2027

5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2016-2027

5.4.1 Novel Approaches Will Drive ADCs Market Growth

5.4.2 Competition for Leading Drugs Will Restrain Growth

5.4.3 Manufacturing ADCs Forms a Challenge

5.5 Adcetris (brentuximab vedotin, Seattle Genetics / Takeda)

5.5.1 Adcetris: Sales 2011-2016

5.5.2 Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation

5.5.3 Expanding Adcetris Indications for Future Revenue Growth

5.5.4 Adcetris Sales Forecast 2016-2027

5.6 Kadcyla (trastuzumab emtansine, Roche)

5.6.1 Mixed Results from Different Clinical Trials

5.6.2 NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List

5.6.3 Kadcyla Sales Forecast 2016-2027

5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)

5.7.1 Mylotarg to be Relaunched?

5.8 Antibody-Drug Conjugate Platforms

5.8.1 Limited Market Opportunity for Radioconjugation

5.8.2 Seattle Genetics’ Platform Accounted for Over 40% of the Pipeline in 2016

5.8.3 ImmunoGen: TAP Technology

5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use

5.8.5 Preclinical Platforms for ADC Development

5.9 ADCs Have Attracted High-Value Deals and will Continue to do so

5.10 Antibody-Drug Conjugates: Pipeline Analysis 2016-2027

5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market

5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs

5.11 Antibody-Drug Conjugates: Phase 3 Pipeline

5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)

5.11.2 Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline

5.12 Antibody-Drug Conjugates: Phase 2 Pipeline

5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)

5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)

5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)

5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)

5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)

5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)

5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)

5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)

5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs

5.13 Antibody-Drug Conjugates: Phase 1 Pipeline

5.14 Antibody-Drug Conjugates: Preclinical Pipeline

5.15 Future Developments in ADC Technology

5.15.1 Site-Specific Linkage for Improved Safety Profiles

6. Engineered Antibodies: Market Forecast and Pipeline 2016-2027

6.1 Defining an ‘Engineered Antibody’

6.2 Market Overview 2017, and the Leading Engineered Antibodies

6.3 Leading Engineered Antibodies: Market Forecast 2016-2027

6.4 The Engineered Antibodies Market: Drivers and Restraints 2016-2027

6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)

6.5.1 Poteligeo Sales Forecast 2016-2027

6.6 Gazyva / Gazyvaro (obinutuzumab, Roche)

6.6.1 Gazyva as a Challenger in the anti-CD20 Market

6.6.2 Competition beyond Rituxan and Biosimilars

6.6.3 Gazyva Receives Second Approval

6.6.4 Gazyva Sales Forecast 2016-2027

6.7 Engineered Antibodies Platforms

6.7.1 Roche Glycart: GlucoMAb - Glycosylation for Improved ADCC

6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC

6.7.3 Glycotope: GlycoExpress

6.7.4 MacroGenics: Fc Optimization

6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain

6.7.6 Other Platforms for Increased Potency

6.8 Engineered Antibodies: Pipeline Analysis 2016-2027

6.9 Engineered Antibodies: Phase 3 Pipeline

6.9.1 Benralizumab (MedImmune / Kyowa Hakko Kirin)

6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)

6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)

6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)

6.9.5 Ublituximab (anti-CD20, TG Therapeutics)

6.10 Engineered Antibodies: Phase 2 Pipeline

6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)

6.10.2 Margetuximab (anti-HER2, MacroGenics)

6.10.3 MEDI-551 (anti-CD19, AstraZeneca)

6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)

6.10.5 Teplizumab (anti-CD3, MacroGenics)

6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)

6.10.7 XmAb5871 (anti-CD19, Xencor)

6.11 Engineered Antibodies: Phase 1 Pipeline

7. Bispecific Antibodies: Market Forecast and Pipeline 2016-2027

7.1 Bispecific Antibodies: Market Overview, 2017

7.2 Bispecific Antibodies: Market Forecast 2016-2027

7.3 The Bispecific Antibodies Market: Drivers and Restraints 2016-2027

7.4 Removab (catumaxomab, Neopharm)

7.4.1 Removab: Sales Forecast 2016-2027

7.5 Blincyto (blinatumomab, Amgen)

7.5.1 Amgen Files a Supplemental Biologics License Application, and the EU approves Blincyto

7.5.2 Blincyto: Sales Forecast 2016-2027

7.6 Bispecific Antibodies Platforms

7.6.1 BiTE Platform: The Current Market Leader

7.6.2 MacroGenics’ DART Platform Holds Promise

7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2016-2027

7.6.4 Other Bispecific Antibody Platforms

7.7 Bispecific Antibodies: Pipeline Analysis 2016-2027

7.7.1 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline

7.7.2 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)

7.7.3 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)

7.7.4 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)

7.7.5 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)

7.7.6 SAR156597 (anti-IL-4 and IL-13, Sanofi)

7.7.7 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)

7.8 Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline

8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2016-2027

8.1 Antibody Fragments and ALPs: Market Overview, 2017

8.2 Antibody Fragments and ALPs: Market Forecast 2016-2027

8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2016-2027

8.4 Kalbitor (ecallantide, Shire): Shire Completes Acquisition of Dyax and adds Kalbitor to Portfolio

8.4.1 Kalbitor: Sales Forecast 2016-2027

8.5 Antibody Fragments and ALPs Platforms

8.5.1 Single-chain Variable Fragment Platforms

8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins

8.5.3 Which Platform Will Lead the Market 2016-2027?

8.6 Antibody Fragments and ALPs: Pipeline Analysis 2016-2027

8.6.1 Ablynx Leads the Pipeline with Six Clinical Projects

8.7 Antibody Fragments and ALPs: Phase 3 Pipeline

8.7.1 Caplacizumab (anti-vWF, Ablynx)

8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)

8.8 Antibody Fragments and ALPs: Phase 2 Pipeline

8.8.1 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)

8.8.2 Ozoralizumab (anti-TNFα, Ablynx )

8.8.3 DLX105 (anti-TNF-α, Delenex Therapeutics)

8.8.4 ESBA1008 (anti-VEGF, Novartis)

8.9 Antibody Fragments and ALPs: Phase 1 Pipeline

8.9.1 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)

8.9.2 ALX-0171 (anti-respiratory syncytial virus)

8.9.3 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)

8.9.4 Other Phase 1 Candidates, and the Preclinical Pipeline

9. Biosimilar Antibodies: Market Forecast 2016-2027

9.1 Biosimilar Antibodies: Market Overview, 2017

9.2 Leading Biosimilar Antibodies in 2016.

9.3 Biosimilar Antibodies: Market Forecast 2016-2027

9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2016-2027

9.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets

9.4.2 Rising Incidence of Cancer will Drive Demand

9.4.3 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition

9.4.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?

10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2016-2027

10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market

10.1.1 Strengths: The Path Towards Market Acceptance

10.1.2 Weaknesses: Multiple Companies Targeting Similar Indications

10.1.3 Opportunities: Novel Platforms

10.1.4 Threats: Entry of Biosimilars

10.2 STEP Analysis of the Next-Generation Antibody Therapies Market

10.2.1 Social Factors: Rising Demand for Cancer Therapies

10.2.2 Technological Developments Will Drive Pipeline Growth

10.2.3 Economic Pressures

10.2.4 Political and Regulatory Issues

10.3 Key Targets for Next-Generation Antibody Development 2016-2027

10.3.1 Oncology Is the Lead Indication in All Sectors

11. Conclusions

11.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2016-2027

11.2 Current Status of the Market and Leading Segments

11.3 Leading Next-Generation Antibody Therapies Profiled in this Report

11.4 Leading Regional Markets

11.5 Development of the Market to 2027

11.6 Technology Platforms Will Continue to Attract Big Pharma Interest

11.7 Most Developers Continue to Target Cancer

11.8 Strategies for Growth in 2016-2027

12. Glossary

Some Associated Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

List of Tables

Table 1.1 (Sample) World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2016-2021

Table 2.1 Monoclonal Antibody Types and Sources, 2017

Table 2.2 The Different Phases of Clinical Trials and What They Assess

Table 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) and Market Share (%) by Segment, 2016

Table 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2016-2021

Table 3.3 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2022-2027

Table 3.4 World Next-Generation Antibody Therapies Market: Revenue ($m) and Market Share (%) by Segment, 2027

Table 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2016

Table 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2016-2021

Table 4.3 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2022-2027

Table 4.4 Revenue ($m) and Market Shares (%) of Leading Regional Next-Generation Antibody Therapies Markets, 2027

Table 4.5 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021

Table 4.6 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027

Table 4.7 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021

Table 4.8 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027

Table 4.9 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021

Table 4.10 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027

Table 4.11 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021

Table 4.12 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027

Table 4.13 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021

Table 4.14 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027

Table 5.1 ADC Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2016-2021

Table 5.2 ADC Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2022-2027

Table 5.3 Seattle Genetics: Adcetris Revenue ($m), 2011-2016

Table 5.4 Total Adcetris Revenue (Seattle Genetics and Takeda): Revenue ($m), 2013-2016

Table 5.5 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 5.6 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), AGR (%), CAGR (%), 2022-2027

Table 5.7 Kadcyla Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 5.8 Kadcyla Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2022-2027

Table 5.9 ADC Pipeline by Platform and Phase, 2016

Table 5.10 Selected Preclinical ADC Development Platforms, 2016

Table 5.11 ADC Pipeline by Indication and Phase, 2016

Table 5.12 ADC Pipeline by Indication and Phase 3, 2016

Table 5.13 Selected Ongoing Clinical Trials for CMC544 (inotuzumab ozogamicin), 2016

Table 5.14 Roche’s Antibody-Drug Conjugates Pipeline, 2016

Table 5.15 Ongoing Clinical Trials for RG7596 (polatuzumab vedotin), 2016

Table 5.16 Antibody-Drug Conjugates: Phase 2 Pipeline, 2016

Table 5.17 Ongoing Clinical Trials for ABT-414, 2016

Table 5.18 Antibody-Drug Conjugates: Phase 1 Pipeline, Table 1, 2015 and 2016

Table 5.19 Antibody-Drug Conjugates: Phase 1 Pipeline, Table 2, 2016

Table 5.20 Antibody-Drug Conjugates: Preclinical Pipeline, 2016

Table 6.1 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2021

Table 6.2 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2022-2027

Table 6.3 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 6.4 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), AGR (%), CAGR (%), 2022-2027

Table 6.5 Total Gazyva Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 6.6 Total Gazyva Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2022-2027

Table 6.7 Engineered Antibodies Pipeline by Company and Phase, 2016

Table 6.8 Selected Licensing Agreements for the Potelligent Platform and Cell Lines, 2008-2015

Table 6.9 Engineered Antibodies Pipeline by Indication and Phase, 2016

Table 6.10 Engineered Antibodies: Phase 3 Pipeline, 2016

Table 6.11 Engineered Antibodies: Phase 2 Pipeline, 2016

Table 6.12 Margetuximab Recent and Ongoing Clinical Trials, 2016

Table 6.13 MEDI-551 Recent and Ongoing Clinical Trials, 2016

Table 6.14 Engineered Antibodies: Phase 1 Pipeline, 2016

Table 7.1 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2021

Table 7.2 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2022-2027

Table 7.3 Removab (Neopharm) Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 7.4 Removab (Neopharm) Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026

Table 7.5 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 7.6 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2022-2027

Table 7.7 Bispecific Antibodies Pipeline by Company and Phase, 2016

Table 7.8 Selected Preclinical Bispecific Antibody Platforms, 2016

Table 7.9 Bispecific Antibodies Pipeline by Indication and Phase, 2016

Table 7.10 Bispecific Antibodies Pipeline by Indication and Phase, 2016

Table 7.11 Bispecific Antibodies: Phase 1/2 Pipeline, 2016, Table 1

Table 7.12 Bispecific Antibodies: Phase 1 Pipeline, 2016, Table 2

Table 7.13 Bispecific Antibodies: Preclinical Pipeline, 2016

Table 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2021

Table 8.2 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2022-2027

Table 8.3 Kalbitor Revenue Forecast (Shire): Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 8.4 Kalbitor Revenue Forecast (Shire): Revenue ($m), AGR (%), CAGR (%), 2022-2027

Table 8.5 Ablynx: Selected Big Pharma Collaboration Agreements, 2012-2015

Table 8.6 Antibody Fragments and ALPs Pipeline by Company and Phase, 2016

Table 8.7 Antibody Fragments and ALPs Pipeline by Indication and Phase, 2016

Table 8.8 Antibody Fragments and ALPs: Phase 1 Pipeline, 2016

Table 8.9 Antibody Fragments and ALPs: Preclinical Pipeline, 2016

Table 9.1 Top Ten Best-Selling Drugs of 2014 (Within the Overall Pharmaceutical Market): Revenues ($bn), Market Shares (%)

Table 9.2 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 9.3 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 9.4 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 9.5 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 9.6 Patent Status of Five Leading mAbs, 2016

Table 10.1 Next-Generation Antibody Therapies Market: STEP Analysis, 2016-2027

Table 10.2 Selected CMOs Investing in Next-Generation Antibody Technologies, 2005-2015

Table 10.3 HER2 and HER3-Targeting Next-Generation Antibodies: Pipeline, 2016

Table 10.4 CD19 and CD20-Targeting Next-Generation Antibodies: Pipeline, 2016

List of Figures

Figure 1.1 Global Next-Generation Antibody Therapies Market Segmentation Overview, 2017

Figure 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2016

Figure 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%) by Segment, 2016-2027

Figure 3.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2027

Figure 3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints, 2016-2027

Figure 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) by Region, 2016

Figure 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m) by Region, 2016-2027

Figure 4.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Region, 2027

Figure 4.4 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027

Figure 4.5 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027

Figure 4.6 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027

Figure 4.7 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027

Figure 4.8 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027

Figure 5.1 ADC Market Forecast: Revenues ($m) and AGR (%), 2016-2027

Figure 5.2 ADC Market: Drivers and Restraints, 2016-2027

Figure 5.3 Seattle Genetics: Adcetris Revenue ($m) and AGR (%), 2011-2016

Figure 5.4 Total Adcetris Revenue (Seattle Genetics and Takeda): Revenue ($m) and AGR (%), 2013-2016

Figure 5.5 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m) and AGR (%), 2016-2027

Figure 5.6 Kadcyla Revenue Forecast (Roche): Revenue ($m), 2016-2027

Figure 5.7 ADC Pipeline by Platform, 2016

Figure 5.8 ADC Pipeline by Phase, 2016

Figure 5.9 ADC Pipeline by Indication, 2016

Figure 6.1 Engineered Antibodies Market Forecast: Revenues ($m), 2016-2027

Figure 6.2 Engineered Antibodies Market: Drivers and Restraints, 2016-2027

Figure 6.3 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), 2016-2027

Figure 6.4 Total Gazyva Revenue Forecast (Roche): Revenue ($m), 2016-2027

Figure 6.5 Engineered Antibodies Pipeline by Company, 2016

Figure 6.6 Engineered Antibodies Pipeline by Indication, 2016

Figure 6.7 Engineered Antibodies Pipeline by Phase, 2016

Figure 7.1 Bispecific Antibodies Market: Drivers and Restraints, 2016-2027

Figure 7.2 Bispecific Antibodies Market Forecast: Revenue ($m), 2016-2027

Figure 7.3 Removab (Neopharm) Revenue Forecast: Revenue ($m), 2016-2027

Figure 7.4 Blincyto Revenue Forecast (Amgen): Revenue ($m) and AGR (%), 2016-2027

Figure 7.5 Bispecific Antibodies Pipeline by Company, 2016

Figure 7.6 Bispecific Antibodies Pipeline by Indication, 2016

Figure 7.7 Bispecific Antibodies Pipeline by Phase, 2016

Figure 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), 2016-2027

Figure 8.2 Antibody Fragments and ALPs Market: Drivers and Restraints, 2016-2027

Figure 8.3 Kalbitor Revenue Forecast (Shire): Revenue ($m) and AGR (%), 2016-2027

Figure 8.4 Antibody Fragments and ALPs Pipeline by Company, 2016

Figure 8.5 Antibody Fragments and ALPs Pipeline by Indication, 2016

Figure 8.6 Antibody Fragments and ALPs Pipeline by Phase, 2016

Figure 9.1 Biosimilar Monoclonal Antibody Market Forecast, Split by Product: Revenue ($bn), 2016-2027

Figure 9.2 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn) and AGR(%), 2016-2027

Figure 10.1 Next-Generation Antibody Therapies Market: Strengths and Weaknesses, 2016-2027

Figure 10.2 Next-Generation Antibody Therapies Market: Opportunities and Threats, 2016-2026